JP2010536386A - 受容体標的化試薬 - Google Patents

受容体標的化試薬 Download PDF

Info

Publication number
JP2010536386A
JP2010536386A JP2010522105A JP2010522105A JP2010536386A JP 2010536386 A JP2010536386 A JP 2010536386A JP 2010522105 A JP2010522105 A JP 2010522105A JP 2010522105 A JP2010522105 A JP 2010522105A JP 2010536386 A JP2010536386 A JP 2010536386A
Authority
JP
Japan
Prior art keywords
cancer
receptor
receptor targeting
targeting reagent
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536386A5 (https=
Inventor
ダニエル エー． バレラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2010536386A publication Critical patent/JP2010536386A/ja
Publication of JP2010536386A5 publication Critical patent/JP2010536386A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010522105A 2007-08-24 2008-08-25 受容体標的化試薬 Pending JP2010536386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95793607P 2007-08-24 2007-08-24
PCT/US2008/074268 WO2009029601A2 (en) 2007-08-24 2008-08-25 Receptor-targeting reagents

Publications (2)

Publication Number Publication Date
JP2010536386A true JP2010536386A (ja) 2010-12-02
JP2010536386A5 JP2010536386A5 (https=) 2011-10-06

Family

ID=40388106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522105A Pending JP2010536386A (ja) 2007-08-24 2008-08-25 受容体標的化試薬

Country Status (5)

Country Link
US (2) US9155798B2 (https=)
EP (1) EP2197909A4 (https=)
JP (1) JP2010536386A (https=)
CA (1) CA2697529A1 (https=)
WO (1) WO2009029601A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020010701A (ja) * 2013-09-24 2020-01-23 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
JP2022530343A (ja) * 2019-04-23 2022-06-29 オーロラ オンコロジー 拡張性組織の治療のための組成物および方法
JP2023554557A (ja) * 2020-12-22 2023-12-27 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｉｌ－４ｒ抗体又はその抗原結合断片の複合物及び医薬用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
DK2462449T3 (en) * 2009-08-03 2017-01-09 Yeda Res & Dev Urinary biomarkers for cancer diagnosis
WO2012027494A1 (en) * 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
IN2015KN00329A (https=) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
CN103865899B (zh) * 2012-12-17 2016-04-27 山西康宝生物制品股份有限公司 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用
US20170209579A1 (en) * 2014-07-24 2017-07-27 Baylor College Of Medicine Non-invasive radiofrequency field treatment for cancer therapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX389194B (es) * 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019073299A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
WO2020081841A1 (en) 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Nk engager molecules and methods of use thereof
WO2022246052A1 (en) * 2021-05-19 2022-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-13ralpha2 targeted immunotoxins and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US142539A (en) * 1873-09-02 Improvement
AU6769998A (en) * 1997-03-26 1998-10-20 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
DE19839671C2 (de) * 1998-09-01 2000-08-03 Forschungszentrum Juelich Gmbh Sensor zur Messung eines Magnetfeldes
US6864359B1 (en) * 1999-02-11 2005-03-08 Xencor Structure-based screening techniques for drug discovery
US20050142539A1 (en) 2002-01-14 2005-06-30 William Herman Targeted ligands
WO2004096254A2 (en) 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Transferrin conjugates for tumor treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013032969; Ｂｉｏｃｏｎｊｕｇ．　Ｃｈｅｍ． Ｖｏｌ．３，　Ｎｏ．１, 1992, ｐｐ．６３-６８ *
JPN6013032971; Ｂｉｏｃｏｎｊｕｇ．　Ｃｈｅｍ． Ｖｏｌ．１４，　Ｎｏ．６, 2003, ｐｐ．１１０７-１１１４ *
JPN6013032973; Ｂｒ．　Ｊ．　Ｃａｎｃｅｒ． Ｖｏｌ．６６，　Ｎｏ．４, 1992, ｐｐ．７１２-７１６ *
JPN6013032974; Ｃｌｉｎ．　Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．６，　Ｎｏ．６, 2000, ｐｐ．２１５７-２１６５ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020010701A (ja) * 2013-09-24 2020-01-23 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
JP2023052641A (ja) * 2013-09-24 2023-04-11 メディシナ セラピューティクス インコーポレイテッド インターロイキン－４受容体結合融合タンパク質及びその使用
JP2022530343A (ja) * 2019-04-23 2022-06-29 オーロラ オンコロジー 拡張性組織の治療のための組成物および方法
JP2023554557A (ja) * 2020-12-22 2023-12-27 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｉｌ－４ｒ抗体又はその抗原結合断片の複合物及び医薬用途

Also Published As

Publication number Publication date
US20110091460A1 (en) 2011-04-21
WO2009029601A2 (en) 2009-03-05
EP2197909A2 (en) 2010-06-23
US9155798B2 (en) 2015-10-13
CA2697529A1 (en) 2009-03-05
EP2197909A4 (en) 2014-12-03
WO2009029601A3 (en) 2010-04-22
US20160000868A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
JP2010536386A (ja) 受容体標的化試薬
US20250333533A1 (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
US10035853B2 (en) Site-specific antibody conjugation methods and compositions
US10308721B2 (en) Anti-DLL3 antibodies and drug conjugates for use in melanoma
JP6233933B2 (ja) 葉酸リセプターα及びβを認識する抗体
US20190201542A1 (en) Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition
AU2014312215A1 (en) Site-specific antibody conjugation methods and compositions
US20030082188A1 (en) Treatment of prostate cancer by inhibitors of NCAM2
EP3080607A2 (en) Novel anti-dpep3 antibodies and methods of use
US20180112004A1 (en) Engineered site-specific antibodies and methods of use
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
JP2019506136A (ja) 新規抗ｅｍｒ２抗体及び使用方法
US20190016812A1 (en) Novel anti-tnfsf9 antibodies and methods of use
JP2010077026A (ja) がん関連マクロファージを標的とした固形がん治療剤
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
WO2025118472A1 (zh) 一种抗met/egfr双特异性抗体及其药物偶联物
JP2025504036A (ja) 親和性が増強された抗ｅｃｍナノボディ－サイトカイン融合体およびその応用
US20230183314A1 (en) Prostate specific membrane antigen binding fibronectin type iii domains and cells comprising the same
EP4707305A1 (en) Anti-cldn6 antibody and use thereof
CN116925220A (zh) Il20rb中和抗体及其医药用途
JP2014091687A (ja) 軟骨又は骨の破壊の診断薬
HK1212220A1 (en) Antigens associated with inflammatory bowel disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131126